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Use of Viral Infections in Animal
Models to Assess Changes in
the Immune System
by Earl R. Kern*
Viral infections in animal models appear to be ideal systems for determining toxicity to the
immune system by environmental substances. Since many viral infections that are utilized in
animals produce systemic disease, these models provide an opportunity to evaluate the interac-
tion between virus and components of host resistance. In these infections it is possible to
delineate the role ofantibody, interferon, cell-mediated immunity, neutrophils and macrophages
in response to infection. A change in any of these components responsible for resistance to a
particular virus may be correlated with an alteration of mortality and pathogenesis ofthe viral
infection. Three experimental viral infections in mice that are potential candidates for use in
determining immunotoxicity are discussed in terms ofthe response of individual components of
resistance to infection and how changes in these components result in alterations of viral
pathogenesis. The resistance to encephalomyocarditis virus infection in mice appears to be
primarily mediated by antibody and interferon while with herpes simplex virus, infections are
mainly controlled through cell-mediated immunity, macrophages, and possibly interferon.
Cellular immunity also appears to be primarily responsible for resistance to cytomegalovirus
infections. Therefore, it is important in the use ofthese systems for evaluating immunotoxicity
to define the pathogenesis ofthe viral infection and the specific host responses to these infections
and to be able to correlate a change in host resistance with an alteration ofthe viral infection.
Interactions between Viruses
and Host Defenses
Viral infections are probably the most common
cause ofmorbidity in man. We are continuallybeing
exposed to a variety of different viruses, often
become infected, but generally recover without seri-
ous consequences. There are a number of viruses,
however, that do have the capability of producing
severe disease in man and in many cases result in
mortality. There are many factors that may play a
roleindeterminingwhethertheinfected host recov-
ers or not; the two most important appear to be the
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virulence ofthe virus and its pathogenesis ofinfec-
tion and the ability of the host's defense mecha-
nisms to control the viral infection. This is a very
complex set of interactions that result in disease
manifestations ranging from complete recovery to
death.
Once the host becomes infected, dependent on
the particular virus, there are a variety ofpossible
patterns of pathogenesis of the viral infection that
may occurinthe host. There may be disease only at
the local site ofinfection such as the upper respira-
tory tract. An example of this type of infection is
caused by rhinoviruses or other viruses which pro-
duce a limited respiratory infection. After infection
at a local site there may be direct spread ofvirus to
other target organs such as the lower respiratory
tract. Influenzavirus, the parainfluenzaviruses and
respiratory syncytical virus can result in this type
of pathogenesis. The virus may spread from an
71initial site of infection to other target organs such
as the lungs, liver, spleen, brain, or skin by way of
the blood stream or the lymphatic system. The
virus may be free in the plasma, be carried within
leukocytes, or in some cases may actually replicate
in the leukocytes. Some of the viruses that are
disseminatedthroughthe hostinthis mannerinclude
measles virus, mumps virus, hepatitis virus, polio-
virus, and the arthropod-born togaviruses. Certain
viruses such as herpes simplex virus and rabies
virus have the capability oftraveling from an initial
site of infection to the central nervous system by
way of direct neural spread. The nature of the
interaction between the infecting virus and the
host's immune system is going to be dependent on
the pathogenesis of the viral infection. The more
generalized the infection is, the greater may be the
role of the host's defense in contributing to the
control of the infection.
There are numerous components of host resis-
tance, both humoral and cellular that may respond
to viral infections. These include antibody produced
byB-lymphocytes, interferon, cytotoxic T-cells, nat-
uralkiller (NK) cells, neutrophils and macrophages.
In addition to these there are also subsets of some
ofthese, particularly the T-lymphocytes, that carry
out different functions. Some subsets may act as
helper cells, while others may actually suppress
certain immune functions. In addition to these indi-
vidual components of host resistance, there are
multiple interactions between the components. It
would appear unlikely that one component of the
immune system is responsible for the recovery of
the host from a viral infection but rather that host
resistance is a complex interaction of many compo-
nents. There is also selectivity in that some compo-
nents appear to be more important in recovery to
certain viral infections than in others.
The interaction between the virus and host can
result in one of a number ofpotential outcomes (1).
These are summarized in Table 1. The first possibil-
ity is that the host is completely resistant and no
infection is established. In this case other factors
thanjustimmunefunctions are undoubtedlyinvolved.
Secondly, the host may undergo a mild or subelini-
cal infection with either a complete recovery or
recovery with a persistent or latent infection. The
third possibility is that the host will suffer from an
acute disease. Depending upon the particular virus
and the ability of the host's immune system to
control the infection, the outcome can be death,
complete recovery, oragain recovery with a persis-
tent or latent infection. Finally, the virus can pro-
duce a persistent infection which may be asymp-
tomatic, may be characterized by periodic recur-
rences, or may continue as alongterm persistent or
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Table 1. Potential results ofvirus-host interactions.
Interaction Result
Host is resistant No infection established
Subclinical infection Complete recovery
Persistent or latent infection
Acute clinical disease Death
Complete recovery
Recovery with persistent or latent
infection
Chronic infection Asymptomatic with latent virus
Latent with recurrence
Persistent-chronic infection
Malignant transformation
chronic infection. The final determination as to
whether most viral infections result in recovery, a
chronic infection or death is probably mediated by
the host's immune system. It is well documented
that many ofthe severe or chronic infections occur
in patients with compromised immune functions.
The outcome of a particular viral infection, thus,
reflects both the virulence of the virus and the
immunocompetence ofthe host. Factors which com-
promisehostdefensemechanismswouldbeexpected
to alter the virus-host relationships, therefore, ani-
mal model infections may be utilized for evaluating
immunotoxicity.
If one is to use the immune system as a target
organ for assessing the effect of environmental
substances, it is necessary to understand how a
change in the immune system might result in a
change in the pathogenesis ofthe viral infection. A
few examples of how an alteration in some of the
components of host resistance might affect viral
replication are shown in Table 2. A suppression in
the synthesis or function of antibody, interferon,
T-cellsormacrophageswouldlikelyresultinenhanced
viral replication and dissemination which we would
predict would result in more serious disease or
enhanced mortality. On the other hand, ifthe sub-
stance happens to induce interferon or activate
macrophages we would predict that in some infec-
tions viral replication would be decreased resulting
in less serious disease and lower mortality. It is
Table 2. Predicted change in viral pathogenesis resulting
from an alteration in components of host resistance.
Component Change Viral replication
Antibody Depression No change, increase
Interferon Induction Decrease
Suppression Increase
T-Cells Suppression Increase
Macrophage Activation Decrease
Suppression or destruction Increase
Environmental Health Perspectivesobvious from the vast information collected in both
man and experimental animals that some compo-
nents of the immune system can be modulated in
either direction. Specific examples of how those
changes can result in the alteration of viral infec-
tions in animals models will be considered subse-
quently.
Use of Animal Models to Assess
Changes in Host Resistance
to Viral Infections
In the development and use of viral infections in
animal models for determining the toxicity of vari-
ous environmental substances anumber ofconcepts
concerning the virus-host relationship need to be
considered. Some of the "ideal" properties of viral
infections in animal models are: the viral infection
should simulate a relatively common human dis-
ease;wheneverpossibletheanimalsshouldbeinfected
by a natural route, preferably by the same manner
in which man becomes infected; a low inoculum of
virus should be utilized so that one does not over-
whelmthe host's immune system; human viruses or
ones closely related should be utilized; the course
and pathogenesis of infection should be similar to
that seen in the corresponding disease in man; and
the host used should have an immune response
similar to that ofman. It is probably not possible to
fulfill all these criteria, however, we should strive
to use as many ofthe properties as possible so that
data collected in these models will be relatively
predictive forwhat we would expect in man. Due to
convenience and cost as well as viral susceptibility,
most animal models have utilized mice. Although
this host is agood one forimmunological studies, its
small size presents major problems fortoxicological
evaluation. Additionally, there may also be differ-
ences in metabolism, pharmacokinetics, etc., ofthe
test substance.
The use of viral infections in animal models to
determine changes in the immune system is ideal
because an effect can be evaluated and correlated
both in the viral infection and in the host's immune
system. The most useful parameters that are used
to determine changes in the viral infection are final
mortality rates, mean survival times, viral replica-
tion in specific target organs, viral replication at
local site of infection and mean lesion scores, time
to healing, etc.
Most commonly used-and, of course, the easi-
est parameter to use-is effect on mortality. Is the
mortality rate enhanced or is the animal protected,
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Table 3. Parameters used to determine alteration of host
resistance: the immune system.
Immune function Test system
Antibody response Specific viral antigen
Other antigens, SRBC, etc.
Interferon response Viral infection
Other inducers
Lymphocyte blastogenesis Nonspecific mitogens
Virus-infected cells
Lymphocyte cytotoxicity
T-Cells Virus-infected cells
NK Cells Tumor cells
Macrophage function Viral replication
Phagocytosis, killing, etc.
Cytotoxic for tumor cells
Protect virus-infected cell
Monolayer
Neutrophil function Chemotaxis, phagocytosis
Chemiluminescence
and does the time period of survival change. Addi-
tional and often more important information can be
gained by determining the effect on viral replica-
tion in specific target organs such as the lung, liver,
spleen, brain or in the nasopharynx, genital tract,
skin lesions, etc. These parameters are generally
more sensitive in determining effects on the viral
infection than is final mortality. There are numer-
ous parameters which can be utilized to determine
alterations of each component of the immune sys-
tem. A partial list of immune functions that could
be used are tabulated in Table 3. One approach
would be to begin with two or three general tests,
then proceed to the use of more specific functional
assays. The major pitfall in the use ofthese in vitro
tests is that they may not necessarily be predictive
ofthe response in the intact animal. Additionally, it
is difficult to evaluate noted changes in an isolated
component when in the intact animal there is cer-
tainly interaction between the various components
along with control mechanisms. If one is able to
correlate changes in the immune system with an
alteration in the pathogenesis ofthe viral infection,
however, valuableinformationconcerningthepoten-
tial toxicity of environmental substances can be
gained.
Potential Model Viral Infections
for Evaluating Immunotoxicity
Fromthe numerous experimental viral infections
ofanimals available, I have selected three as exam-
ples ofsystems that might be used for determining
effects on the immune system. These models were
73Table 4. Potential model systemic viral infections.
Infection Parameters
Encephalomyocarditis (EMC) virus infection of mice Pathogenesis of disease
Role of antibody
Role of interferon
Herpes simplex virus (HSV) infection of mice Pathogenesis
Role of cellular immunity - immunosuppression
Role of macrophage - suppression or activation
Role of interferon
Murine cytomegalovirus (MCMV) infection of mice Pathogenesis
Role of cellular immunity - immunosuppression
Alteration of host resistance by infection
selected not necessarily because they are the best
but because there is a considerable amount ofinfor-
mation available on the pathogenesis of the viral
infections and on the role ofthe immune system in
the control of these infections. The three viruses
are relatively easy to work with and do not have a
significant health hazard when used under reason-
able laboratory conditions. These threemodelinfec-
tions and some ofthe virological and host resistance
parameters that have been evaluated in each sys-
tem are shown in Table 4. For each of the model
infections the pathogenesis and the role of some of
the key components ofhost resistance inthe control
of the infection will be presented.
Encephalomyocarditis (EMC) Virus
Infection of Mice
This experimental system is a model of human
enterovirus infections caused by the Echo viruses,
Coxsackie viruses, and polioviruses. After intra-
peritoneal (IP) or intranasal inoculation of mice
with EMC virus, the pathogenesis ofthis infection
is characterized by an initial viremia followed by
replication of virus in the heart and then the brain
Table 5. Effect of administration of anti-EMC antibody on
mortality of x-irradiated, EMC virus-infected mice.a
Treatment Mortality, %
EMC virus only 12
x-Irradiation only 5
EMC + x-irradiation 90
EMC + x-irradiation + antibody at 90
-24 hr 0
+24 hr 20
+48 hr 35
+72 hr 55
+96 hr 80
aModified from Murphy and Glasgow (5).
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(2-4). The animals generally die on days 6-8. Clear-
ance of virus from the blood is associated with an
early rise in interferon in the serum followed by
antibody production. Therefore, both ofthese com-
ponents of host resistance appeared to be involved
in recovery from this infection. To determine the
roleofantibody, Murphyand Glasgow (5)x-irradiated
mice priortoinfectionwith asublethal dose ofEMC
virus (Table 5). Either EMC virus infection or
x-irradiation alone resulted in only a low mortality,
whereas the combination of the two resulted in a
90% mortality, and no antibody could be detected in
these animals. In contrast, however, when the
x-irradiated animals infected with EMC virus were
given passive antibody early in the course of the
infection, most of the mice were then protected.
These data indicate that the production ofantibody
by B-cells is certainly involved in recovery from
this infection.
To evaluate the role of interferon in the EMC
virus infection, two types ofexperiments have been
performed. In the first case mice were inoculated
with EMC virus and then given either passive
interferon or poly I:C, which is an inducer ofinter-
feron, to determine if enhancing the amount of
circulating interferon might result in the protection
of the infected animals. In the second case, mice
inoculatedwith EMC virusweregivenanti-interferon
antibody to determine if elimination of interferon
would result in the enhancement of mortality. The
effect of treatment with passive interferon or poly
I:C on the mortality of mice inoculated with EMC
virus is presented in Table 6. The untreated control
mice had a final mortality of 83%, while those
treated shortly after infection either with inter-
feron or the inducer were protected. Protection of
these animals was associated with a significant alter-
ationinthe pathogenesis ofthe infection. Intreated
animals there was no detectable viremia and no
seeding of the heart or brain (3,4). The effect of
anti-interferon antibody on EMC virus infection of
mice is shown in Table 7. When mice were inocu-
Environmental Health PerspectivesTable 6. Effect of treatment with exogenous interferon or
poly I:C on mortality of mice inoculated with EMC virus.
Mortality
Treatment n/tot % p value
None 33/40 83
Exogenous interferon
-1 hr 0/15 0 < 0.001
+1 hr 2/15 13 < 0.001
+24 hr 11/15 73 N.S.
Poly I:C
-6 hr 1/25 4 <0.001
+lhr 1/24 4 <0.001
+24 hr 10/25 40 < 0.01
Table 7. Effect of anti-interferon globulin on EMC virus
infection of mice.a
Virus dilution Treatment Mortality, %
1076 None 100
Normal globulin 100
Anti-IFN globulin lOOb
10-7 None 0
Normal globulin 15
Anti-IFN globulin lOOb
10e None 0
Normal globulin 0
Anti-IFN globulin 80
aModified from Gresser et al. (6).
bMice treated with anti-interferon globulin died 3-5 days
earlier than untreated mice.
lated with a concentration of virus that resulted in
100% mortality, the ones treated with antibody to
interferon died3-5days earlierthanuntreated ones.
If the viru§ inoculum was reduced to where no
control animals died, the administration of anti-
interferonantibodyresultedin 100%mortality. Addi-
tionally, the enhancedmortalityinantibody-treated
mice was correlated with a dramatic increase in
viral replication in critical target organs (6). These
datastrongly suggest thatinterferon isalsoinvolved
in host resistant to this type of viral infection.
Enhancement of interferon production results in
protection of the animal, while inhibition of the
interferon response results in a marked enhance-
ment of the infection. In experimental EMC virus
and other similar enterovirus infections both anti-
body and interferon appear to be primarily respon-
sible for resistance. Cellular-mediated responses
appear to be less important.
Herpes Simplex Virus (HSV)
Infection of Mice
Herpes simplex virus is the causative agent of a
variety ofdiseases in manincludingherpeslabialis,
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herpes genitalis, encephalitis, and disseminated infec-
tion in the neonate. There are two major antigenic
types. The type 1 strains are generally associated
with infections of the mouth, face and the central
nervous system in adults and the type 2 strains
which generally are responsible for genital infec-
tions and disseminated diseaseinneonates. Amodel
systemic infection may readily be established in
adult mice by IP administration of most type 2
strains; however, they are considerably more resis-
tant to type 1 strains. In most cases, immunosup-
pressive agents need to be used prior to IP chal-
lenge with type 1 strains. For localized infections of
the orofacial or genital areas either types can be
used. Since the role ofthe immune system in local-
ized HSV infection remains poorly defined this dis-
cussion will be limited to the use of systemic infec-
tionsinmice. Whenmiceareinoculatedwith HSV-2,
the pathogenesis of the infection can be variable
depending on the age ofthe animal and the route of
viral inoculation. When three-week-old female mice
are inoculated IP, virus is first detected in the gut,
liver and spleen, and later on in the lung, brain and
spinal cord. Virus is sporadically recovered from
the blood. If a more natural route of infection is
used by inoculating mice intranasally with HSV-2,
virus is first detectable in the lung, with subse-
quent spread ofvirus through the blood to the liver
and spleen. Concomitantly, virus also spreads from
the nasopharynx by way oftrigeminal nerves to the
brain (7). Inboth ofthese models there is a general-
ized infection involvingmultiple target organs, par-
ticularly those containing the cellular components
ofhost resistance such as the liver and the spleen.
Since mostpeoplewhohaverecurrent HSVinfec-
tions of the oral or genital regions also have high
levels of circulating antibody, this component of
immunity is probably not a major factor in host
resistance to this virus. However, it has been dem-
onstrated thatthe presence ofantibody can prevent
reinfection or result in less severe disease. Mem-
bers ofthe herpesvirus group, including HSV, cyto-
megalovirus and varicella-zoster virus, frequently
causeseverediseaseinimmunocompromisedpatients,
suggestingthatcell-mediated immunefunctionsmay
be the most important part of host resistance to
these viruses. As mentioned previously, adult mice
are highly resistant to infections with HSV-1. In
the animal model, the use of immunosuppressive
agentssuch ascyclophosphamide oranti-lymphocyte
serum which destroys T-lymphocytes dramatically
increase the susceptibility ofanimals to HSV (8,9).
One representative experiment in which suscepti-
bility ofmice to HSV-1 given either orally or IP is
shown in Table 8. Increased mortality was associ-
atedwithenhancedviralreplicationintargetorgans
75Table 8. Effect ofcyclophosphamide (CPA) immunosuppres-
sion on mortality of herpes simplex virus (HSV) type 1
infection in adult mice.a
Mortality
Treatment n/tot %
HSV (IP) control 19/40 48
HSV (IP) + CPA 29/30 97
HSV (oral) control 1/30 3
HSV (oral) + CPA 13/30 43
aFrom Rajcani et al. (10).
(10). From the data available it seems certain that
T-cells are involved in resistance to HSV.
Another component that appears to be an impor-
tant determinant in resistance to HSV is the mac-
rophage. These cells appear to be of major impor-
tance in the development of age-related resistance
in that it has been shown that HSV will replicate in
macrophages from susceptible newborn animals,
but not in macrophages from resistant adult mice
(11,12). Two general types of experiments further
document the role of the macrophage in resistance
to HSV. Agents such as silica which transiently
destroy macrophages can result in enhanced sus-
ceptibility. The effect of silica treatment on the
mortality of mice subsequently inoculated IP with
HSV-2 is shown in Table 9. In two experiments
with two different silica preparations, mortality
was enhanced significantly compared to control ani-
mals. The increase in mortality was correlated with
a change in the pathogenesis of the HSV-2 infec-
tion. In controlmice, low levels ofvirus were found
sporadically in the visceral organs, and virus was
not detected in the brain until late in the course of
infection. In contrast, in silica-treated mice, virus
was present in high titers in target organs 2 days
after infection, and virus was detected in the brain
on day 4 (13). The second concept that can be used
to implicate the macrophage as a primary compo-
nent ofhost resistance to HSV comes from the fact
Table 9. Effect of silica treatment on systemic HSV-2
infection.a
Log LD50
Normal Silica-
mice treated mice
Experiment 1
Sargeant-Welch Silica 2.7 3.7
Dorentruper Silica 2.7 3.7
Experiment 2
Dorentruper Silica 2.7 3.7
aFrom Morahan et al. (15).
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Table 10. Effect of immunopotentiators on resistance to
HSV-2 infection in adult mice.
Mortality
Treatment n/tot % p value
PBS 15/15 100
C. acnes 3/15 20 < 0.05
C. parvum 4/14 29 < 0.05
Pyran 7/15 47 < 0.05
that immunomodulators such as BCG, C. parvum
and pyran which have been shown to activate mac-
rophages orincreasetheirfunctionresultinincreased
resistance to HSV infection (13-15). An example of
the use ofthese substances to increase resistance to
HSV-2 is shown in Table 10. To be effective in
increasing resistance the substances must be given
5-14 days prior to infection. In these experiments
the enhanced protection also correlated with the
absence ofvirus in the target organs, and with the
activation of macrophages by these agents. There-
fore, resistance to HSV infection can be modulated
by manipulation of the macrophage population.
Destruction or suppression ofmacrophages results
in increased susceptibility, while enhancement of
macrophageactivityresultsinincreasedresistance.
To investigate the role ofinterferon in host resis-
tance to HSV, similar experiments to those per-
formed in the EMC virus infection have been car-
riedout. Exogenousinterferon orinterferoninducers
have been used to enhance resistance, and anti-
interferon antibody to determine if resistance is
depressed. In a representative experiment shown
inTable 11 mice wereinoculated with HSV-2 bythe
IP route and then treated with either exogenous
interferon or poly I:C at various times after infec-
tion. In the PBS-treated control animals, 95% of
the animals died; in those treated with either inter-
feron or the inducer, significant protection was
observed when therapy was initiated as late as 48
hr post infection (16). In another model infection
utilizing newborn mice inoculated by the intranasal
route with HSV-2, treatment with poly I:C com-
pletely inhibited viral replication in lung, liver and
spleen but not brain. Ingeneral, the control ofHSV
replication in target organs correlated with the
induction of interferon in those tissues (17). From
these and other data in the literature it is apparent
that interferon or interferon inducers can protect
animals against HSV infection and suggest that
interferon is involved in resistance to and recovery
from HSV infection. Data which more directly indi-
cate that interferon is involved in resistance to
HSV comes from the experiments ofGresser et al.
(18), who used anti-interferon antibody to abolish
Environmental Health PerspectivesTable 11. Effect of treatment with interferon or poly I:C on
mortality of mice inoculated IP with HSV type 2.
Mortality
Treatment n/tot S p value
PBS 24/25 96 -
Interferon
+ 1 hr 7/14 50 < 0.01
+24 hr 4/14 29 < 0.001
+48 hr 4/15 27 < 0.001
Poly I:C
+ 1 hr 15/25 60 < 0.01
+24 hr 8/25 32 < 0.001
+48 hr 8/15 53 < 0.01
Table 12. Effect of anti-interferon globulin on HSV type 1
infection of mice.a
Virus dilution Treatment Mortality, %
102 Normal globulin 50
Anti-IFN globulin lOOb
10e Normal globulin 60
Anti-IFN globulin lOOb
104 Normal globulin 0
Anti-IFN globulin 100
aModified from Gresser et al. (18).
bMice treated with anti-interferon globulin died 3-5 days
earlier than control mice
the interferon response inmiceinfected with HSV-1
(Table 12). In these animals the mortality rate was
increased and viral replication in target organs was
enhanced (18). These results in mice infected with
HSV, alsodemonstrate thatresistance canbe altered
in both directions by either increasing the amount
ofinterferon produced or by inhibiting the endoge-
nous response.
Murine Cytomegalovirus (MCMV)
Infection of Mice
Cytomegalovirus infection of humans can result
in a variety of diseases, including congenital infec-
tion of the fetus, a mononucleosis-like syndrome in
patientsreceivingtransplants orbloodtransfusions,
achronicinfectioninvolving numeroustarget organs
and an asymptomatic infection ofchildren or adults.
Since the cytomegaloviruses exhibit strict species
specificity, it is necessary to use closely related
animal strains in experimental infections. When
mice are inoculated IP with MCMV, the virus repli-
cates to high titers in the liver, spleen, kidney and
lung (19). This is a generalized infection involving
all the major target organs and there should be
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maximum interaction between the viral infection
and the immune system allowing one to identify
numerous potential alterations of the immune re-
sponse. Antibody has not been identified as a criti-
cal component ofhost resistance to CMV, although
there is evidence that immunization may be effec-
tive in prevention ofinfection. The use ofinterferon
or interferon inducers in animal or human studies
have not resulted in significant protection against
infection. Cytomegalovirus infections are a particu-
lar problem in the immunocompromised patient,
and there are numerous studies in man and experi-
mental animals which indicate that cell-mediated
immunity is the primary component responsible for
resistance to these infections. The effect of immu-
nosuppression by cyclophosphamide, prednisolone
or anti-lymphocyte serum on the immune response
and mortality of mice infected with MCMV are
summarized in Table 13. In immunosuppressed ani-
mals the mortality rate and reactivation of latent
viruswerebothincreased. Thecell-mediatedimmune
response to MCMV antigen, and the response to
three mitogens were all suppressed. The develop-
ment of humoral immunity did not appear to be
altered (20,21). Similar data supporting the impor-
tance ofcell-mediated immunity to infections bythe
herpesvirus groupinhumans have alsobeenreport-
ed.
Evidencehasbeenpresented which suggeststhat
experimental viral infections in animals provide
ideal models for evaluating the potential immuno-
toxicity of substances to which humans may be
exposed. It is important to note, however, that
viral infections by themselves may result in alter-
ations of immune responses in the infected host.
These effects of the virus, therefore, must also be
defined in any animal model utilized for toxicity
studies. The MCMV infection ofmice is an excellent
example of how a viral infection can enhance or
suppress individual components of host resistance
(22-26). (Table 14). It appears from these data that
Table 13. Effect of immunosuppression on humoral and
cellular immunity to murine cytomegalovirus infection in
mice.a
Component tested Result
CF antibody Not altered
CMI to MCMV antigen Suppressed
Mitogen response
PHA Suppressed
Con A Suppressed
LPS Suppressed
Mortality Increased
Reactivation of latent virus Increased
aCompiled from Howard et al. (20) and Mayo et al. (21).
77Table 14. Alteration of host resistance by murine cytomega-
lovirus infection.
Component tested Result
Antibody response, MCMV Ag Not altered
Antibody response, other Ags Suppressed
CMI to MCMV Ag Not altered
Mitogen response - PHA Suppressed
Mitogen response - Con A Suppressed
Mitogen response - LPS Suppressed
T-cell cytotoxicity Not altered
NK cell cytotoxicity Enhanced
Interferon response to MCMV Not altered
Interferon response to other inducers Suppressed
Macrophage function Enhanced
aCompiled from data of Howard et al. (24), Kelsey et al. (22),
Quinnan et al. (23), Stringfellow et al. (25) and Schleupner et al.
(26).
Table 15. Potential effects ofviral infections on the immune
system.
Effect
Suppression of antibody response
Suppression of interferon production
Suppression oflymphocyte response
Nonspecific mitogen response
Specific antigen response
Suppression of macrophage function
Potentiation of macrophage function
specific responses to the virus, that is the antibody
response to MCMV antigen, CMI to MCMV anti-
gen, T-cell cytotoxicity to virus-infected cells, NK
cell cytotoxicity, the interferon response to MCMV
and macrophage function are either enhanced or
not altered during acute MCMV infection. Certain
other responses, however, such as antibody pro-
duction to other antigens, lymphocyte response to
mitogens, and the interferon response to other
inducers are generally suppressed. This would indi-
cate that there is specificity and regulation in the
humoral and cellular response to viral infections.
Immunosuppression of certain immune responses
has also been documented in other viral infections
such as influenza and measles (Table 15). In deter-
mining the effect of environmental substances on
the immune system during a model viral infection,
the components of host resistance for evaluation
will have to be selected carefully such that an effect
induced by aforeign substance can be distinguished
from those caused by the viral infection.
Experimental viral infections in animals appear
to be ideal models for assessing changes in the
immune system. The virus-host interaction, how-
ever, is extremely complex, involving numerous
components of host resistance. In any particular
viral infection there is no one component responsi-
ble for resistance, instead there are multiple inter-
actions among the various components. This con-
ceptis supportedbytherelationshipofmacrophages
and B-cells in the production of antibody, the acti-
vation ofmacrophages by interferon, and the regu-
latory activity of helper and suppressor cells and
lymphokines. One of the limitations in the use of
these models is that the viral infection may also
alter host responses. It should be stressed that the
animal model cannot be utilized effectively by just
treating the animal with a particular substance,
infecting with virus and then haphazardly deter-
mining effects on components ofhost resistance. To
provide optimalinformation it is important that one
first understand the pathogenesis ofthat particular
viral infection being used and the specific and
nonspecific host responses to that infection.
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